Improvement in bother associated with erectile dysfunction (ED) is an important aspect of successful treatment of ED. Changes in erectile function and the bother associated with ED were assessed in this analysis of pooled data from five 12-week, multicenter, randomized, double-blind, placebo-controlled, flexible-dose studies of sildenafil. Men who received sildenafil (n ¼ 578, vs placebo, n ¼ 550) had significantly greater (least squares mean7s.e.) improvement in erectile function (EF) domain scores of the international index of erectile function (IIEF) (10.070.3 vs 1.070.3, Po0.0001) and in erection distress scale (EDS) total transformed score (18.870.8 vs 4.870.9, Po0.0001). Scores on individual questions of the EDS were 24-65% higher after treatment with sildenafil (vs 8-12%, for placebo). The change in EF domain score correlated positively with the change in total transformed EDS score (0.43, Po0.0001). Successful treatment of ED with sildenafil may reduce the bother associated with ED.
Introduction
The impact of erectile dysfunction (ED) frequently extends beyond a man's physical function; it can have a psychological effect on a man and his partner, producing bother. Consequently, the emotional toll that ED can have on men and their partners should be considered in the diagnosis and management of ED. Among its three specific diagnostic criteria for ED, the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition includes 'The disturbance causes marked distress or interpersonal difficulty. ' 1 A global survey of 13 618 men from 29 countries found that 13-28% have ED, 2 and a survey of 1481 men in the Netherlands found that, of those with ED, 67% were bothered by it and 85% wanted help for their condition. 3 However, physicians do not always ask about ED during primary care visits, and ED continues to be under-diagnosed. 4, 5 A review of the literature investigating symptom distress revealed that the terms 'bother' and 'distress' are often used interchangeably and can be applied to varying levels of symptom severity. 6 Moreover, bother is associated with different aspects of a medical condition and may be difficult to quantify. For some, the bother associated with a symptom may be linked to the degree of functional impairment, whereas for others it may be associated with the social significance of the symptom.
Left untreated, the emotional bother associated with ED can significantly impact important psychosocial factors, including self-esteem and confidence, and damage personal relationships. [7] [8] [9] In their Consensus Development Panel on Impotence, the National Institutes of Health recommended that studies continue to investigate the social and the psychological effects of ED in patients and their partners. 10 However, there are few data on the effect of ED and its treatment on bother associated with ED. This may be due in part to the absence of data from an instrument designed to assess the bother or distress that is specific to ED.
The erection distress scale (EDS) is a five-item ED-specific questionnaire that was derived from the six items of the Health Distress scale of the validated Medical Outcomes Study Health Perceptions Index. 11 The EDS assesses frustration, feeling weighed down, discouragement, despair and worry (Table 1) . It has been used in several controlled clinical trials of sildenafil citrate (Viagra, Pfizer Inc., New York, NY, USA) beginning with those that established efficacy of sildenafil. [12] [13] [14] [15] Using pooled data from five clinical trials, we used outcomes on the EDS to investigate the degree of bother in men with ED.
Methods

Study design
This was an analysis of pooled data from five similar, 12-week, multicenter clinical trials of sildenafil which were conducted between 1995 and 1999. Each was randomized, double-blind, placebo-controlled and flexible-dose (50 mg initial dose adjustable to 25 or 100 mg), and assessed the efficacy of sildenafil in men with ED of broadspectrum etiology. Study drug was to be taken as needed approximately 1 h before sexual activity, but not more than once daily for 12 weeks.
Inclusion and exclusion criteria
Men X18 years of age with a documented clinical diagnosis of ED of at least 6 months duration, who were in a stable relationship for X6 months, were eligible. Major exclusion criteria included psychiatric disorder; poorly controlled diabetes; untreated proliferative retinopathy; hematologic, renal or hepatic disorders; significant cardiovascular disease; history of stroke or myocardial infarction in the last 6 months; or resting blood pressure o90/ 50 mm Hg or 4180/110 mm Hg. Men were also excluded if they used nitrates or nitric oxide donors or were taking any other treatment for ED.
Study outcomes
The study outcomes were changes in erectile function and bother associated with ED from study baseline (week 0) to the end of treatment (EOT; week 12). Erectile function was assessed using the erectile function (EF) domain of the international index of erectile function (IIEF). 16 The severity of ED was determined based on the EF domain score categories from Cappelleri et al.:
17 severe (6-10), moderate (11) (12) (13) (14) (15) (16) , mild-to-moderate (17-21), mild (22) (23) (24) (25) ED and no ED (26) (27) (28) (29) (30) . Bother associated with ED was assessed at baseline and EOT using the EDS. Possible responses for the individual EDS questions (items) range from 1 (all of the time) to 6 (none of the time), such that higher scores indicate less bother. The sum of individual EDS item scores (total raw score) was transformed onto a 100-point scale using the following formula: transformed score ¼ 100 (raw total score/30). Using this transformation, the lowest total transformed score is 16.7 (all of the time) and the highest is 100 (none of the time). Improvements in EF domain scores and EDS scores were assessed overall and by baseline ED severity. The data from men who took at least 1 dose of study drug and provided post-baseline data for the IIEF and EDS were included in the intent-to-treat (ITT) analysis for efficacy.
Psychometric analyses were conducted on the EDS using data collected at baseline (week 0) and EOT (week 12) from the five-pooled trials included in this study. Analyses included exploratory factor analyses (unrotated: eigenvalues X1 (Kaiser criterion) and the scree plot), item loading onto the factor (a loading of 40.3 delineated unidimensionality of the items), Pearson inter-item correlations to identify any potential redundancy (r40.8) or outliers (ro0.3) in items, the quality of completion (rate of missing items from all EDS administrations), the distribution of scores (the skewness statistic), floor and ceiling effects in score distribution (endorsement of 450% for the minimum and maximum scores, respectively) and internal consistency (Cronbach's a). Known-groups validity was evaluated by determining the ability of the EDS item scores to differentiate between ED severity groups as defined by scores on the EF domain of the IIEF. It was not possible to analyze convergent validity of the EDS because the population lacked results on a validated quality of life instrument.
Statistical analyses
The differences in change from baseline to EOT (last observation carried forward (LOCF)) scores between sildenafil-and placebo-treated patients were assessed using analysis of covariance, with terms for treatment group, study and baseline scores as covariate. This analysis was applied to EF domain scores, individual EDS question scores and the total Were your erection problems a worry in your life?
Responses to the EDS were 1, all of the time; 2, most of the time; 3, a good bit of the time; 4, some of the time; 5, a little of the time; and 6, none of the time. Higher scores indicate less ED-related bother and distress. The transformed EDS total score ¼ 100 Â (total raw score/30). Using this transformation, the lowest possible total transformed score is 16.7 (all of the time) and the highest is 100 (none of the time). 
Results
Patients
A total of 1270 men (placebo ¼ 631, sildenafil ¼ 639) were assigned to treatment in the five pooled trials. Of these, 1128 (placebo, n ¼ 550; sildenafil, n ¼ 578) were included in the ITT analysis for efficacy and 1115 responded to EDS items at baseline or EOT. Both treatment groups were well balanced for age, race and duration and etiology of ED at baseline (Table 2) . Baseline scores on the EF domain of the IIEF were comparable for patients who received placebo and sildenafil and indicated that the majority of patients had severe ED (placebo ¼ 60%, sildenafil ¼ 58%).
Erectile function domain
Mean (standard deviation (s.d.)) baseline scores on the EF domain were similar for men randomized to receive sildenafil, 10.3 (6.4), or placebo, 10.5 (6.5). At EOT, scores for men taking sildenafil were higher, 20.3 (9.0), than scores for men taking placebo, 11.3 (7.4), with the change from baseline to EOT in scores significantly greater for men taking sildenafil (least squares (LS) mean change7standard error (s.e.), 10.070.3 vs 1.070.3, Po0.0001). Compared with patients taking placebo, patients taking sildenafil had greater improvements in EF domain scores, regardless of ED severity at baseline ( Figure 1 ). The proportion of patients who improved by 1 or more ED severity category ranged from 64 to 89% for patients who were randomized to receive sildenafil compared with 16-34% of patients who were randomized to receive placebo ( Figure 2 ). Compared with placebo, fewer patients who received sildenafil had no change in ED severity and more improved by 1 ED severity category or more. After 12 weeks of double-blind treatment, 40% (219 of 551) of patients taking sildenafil, compared with 6% (32 of 500) of patients taking placebo, improved from having had (Figure 3a) . Total mean transformed EDS scores ranged from 52 to 65 across all ED severities at baseline indicating that even mild ED was a bother a good bit of the time. The scores on the individual questions of the EDS indicated that frustration with one's erection problems was more common than were feelings of being weighed down, discouraged, having despair or worry, independent of ED severity at baseline (Figure 3b ). At EOT, the mean (s.d.) total transformed EDS scores were higher for men taking sildenafil, 72.7 (22.8), compared with scores for men taking placebo, 58.4 (21.5), with change from baseline to EOT in total transformed EDS score significantly greater for men taking sildenafil (LS mean change7s.e., 18.870.8 vs 4.870.9, Po0.0001). Improvements in total transformed EDS scores were observed across all baseline ED severity categories ( Figure 4 ). The mean total transformed EDS scores at EOT across baseline ED severities ranged from 56 to 70 for patients taking placebo and from 70 to 88 for patients taking sildenafil. Scores at EOT on the individual questions of the EDS were higher for men taking sildenafil compared with scores for men taking placebo (Table 3 ). The percentage change from baseline to EOT in mean scores for the individual questions of the EDS ranged from 24 to 65% for sildenafil-treated patients and from 8 to 12% for placebo-treated patients. The greatest improvements were noted in frustration (EDS Q1, placebo ¼ 12%, sildenafil ¼ 65%) and discouragement (EDS Q3, placebo ¼ 11%, sildenafil ¼ 45%) with erection problems. The unidimensionality of the EDS (for example, all five items measure a single factor) was supported by eigenvalues X1, the scree plot, loading of all items onto the factor with a loading of 40.3 (range, 0.71-0.85) and the absence of redundant or outlier items. The rate of missing items was very low (3/ 1115 ¼ 0.27%), skewness was between -1 and 1 at baseline (range, -0.28-0.72) and at EOT (À0.79-0.14), there were no floor or ceiling effects in responses, and internal consistency was excellent (Cronbach's a ranged from 0.87 to 0.90 across the five items at baseline and from 0.91 to 0.93 at EOT). Known-groups analysis showed that the EDS score differentiated all adjacent categories of ED severity between 'no ED' and 'moderate ED,' with the EDS score decreasing (increased bother) as ED severity increased, but that the EDS score did not differentiate between 'moderate ED' and 'severe ED'. 17 severe (p10), moderate (11) (12) (13) (14) (15) (16) , mild-tomoderate (17-21), mild (22) (23) (24) (25) and no ED (X26). ED, erectile dysfunction; EDS, erection distress scale; P, placebo; S, sildenafil.
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Correlations between changes in EF domain and EDS scores
The Pearson's correlation coefficient between change from baseline to EOT in EF domain score and the change from baseline to EOT in total transformed EDS score was 0.38 (95% CI, 0.33-0.43). Correlation coefficients by treatment group were comparable (data not shown). Positive correlations were also observed between change in EF domain score and change in the individual questions of the EDS (Table 4) . Large improvements from baseline were observed in scores on both the EF domain and the EDS Q1 (frustration), and these scores were positively correlated, 0.45 (95% CI, 0.40-0.49). The Pearson's correlation coefficients between the change from baseline to EOT in scores for each of the 15 individual IIEF questions and the change from baseline to EOT in the scores for each of the five EDS questions were all positive. Although all correlations were significant (Po0.0001), the largest correlation coefficients were between improvement in individual EDS questions and improvement in satisfaction with sex life (IIEF Q13, r value range, 0.26-0.46) and improvement in confidence to get and keep an erection (IIEF Q15, r value range, 0.22-0.44). Lower correlation coefficients (r value range, 0.03-0.18) were observed between change from baseline in scores on EDS questions and change from baseline in scores on other questions of the IIEF (Q6, number of intercourse attempts; Q9, frequency of ejaculation; Q10, frequency of orgasm; Q11, frequency of sexual desire and Q12, level of sexual desire). Figure 4 Change from baseline to the end of treatment in EDS scores. Mean total transformed EDS score was determined at baseline and at the end of treatment (week 12, last observation carried forward) for patients taking placebo or sildenafil, and LS mean change in total transformed EDS score from baseline to EOT was determined using an analysis of variance model with terms for treatment, study and baseline as the covariates. The severity of ED was determined using EF domain scores: 17 severe (p10), moderate (11) (12) (13) (14) (15) (16) , mild-to-moderate (17-21), mild (22) (23) (24) (25) and no ED (X26). The least squares mean change in total transformed EDS score was assessed in groups subdivided by baseline ED severity. LS means, s.e. and P values were based on ANCOVA models with terms for treatment, study and baseline as covariate. ANCOVA, analysis of covariance; ED, erectile dysfunction; EDS, erection distress scale; EF, erection function; IIEF, international index of erectile function; LS, least squares. *Po0.005 versus placebo.
w Po0.0001 versus placebo. 
Discussion
The current analysis of pooled data from five randomized, double-blind, placebo-controlled trials of sildenafil revealed that the EDS is a unidimensional instrument with good internal consistency, which differentiates between men with no ED and those with ED. EDS scores showed that men with ED reported frequent frustration and discouragement with their erection problem at baseline. Even those with mild ED reported such bother. With sildenafil treatment, erectile function improved, and a large proportion of men shifted from having EF domain scores that indicated mild, mild-to-moderate, moderate or severe ED to having scores that indicated having no ED. Improvements in erectile function correlated positively with change in EDS scores, indicating a reduction in bother, particularly frustration and discouragement with erectile problems, but also feeling weighed down, having despair or worrying about ED. Change in EDS scores indicating a reduction in bother also correlated positively with increased satisfaction with sex life (assessed with IIEF Q13) and increased confidence to get and keep an erection for a satisfactory sexual experience (assessed with IIEF Q15). Consistent with the improvements in bother observed in this study, randomized, double-blind trials of men treated with sildenafil for ED have revealed robust improvements in other measures of psychological function. Sildenafil treatment resulted in improved scores on the ED-specific self-esteem and relationship (SEAR) questionnaire, [18] [19] [20] a validated patient-reported outcome that includes components that can assess the impact of ED on emotional well-being (that is, self-esteem, confidence and relationships). 21 In these SEAR trials, improvements in erectile function were positively and significantly correlated with improvements in these measures of emotional well-being. 18 Furthermore, in trials that compared IIEF and SEAR scores of men with and without ED, men with ED and treated with sildenafil had improvements in scores to near normal across all ED severity categories. 22, 23 Moreover, a trial of men with ED and comorbid depression revealed significant improvements in erectile function and coincident improvements in depressive symptom scores after treatment of ED with sildenafil. 24 Because, as we have shown, even mild ED can have a negative psychological impact, early detection and successful treatment of the physical symptoms of ED may reduce its psychological impact.
ED affects a man's ability to have sexual relations with his partner and is, thus, recognized as a couple's problem. 25 Improvement in a man's erectile function is clearly associated with improvements in his emotional function, which can extend beyond the patient and positively affect his partner. In a study of men with ED and their partners who reported that sexual intercourse was satisfactory about half of the time or less often, treatment of men's ED with sildenafil significantly improved satisfaction for both the patient and the partner. 26 The partners' responses on the Female Partner ED Subject questionnaire (FePEDS) and the Female Sexual Function Inventory revealed that partners of men who received sildenafil for ED had greater improvements in sexual enjoyment and satisfaction than did partners of men who received placebo. These data also revealed a similar distribution for improvement in the man's IIEF scores and his female partner's improvement in FePEDS scores. 27 These data indicate that improvement in a man's erectile function after treatment with sildenafil is strongly associated with his partner's improvement in sexual satisfaction.
A potential limitation in using the EDS to assess the emotional impact of ED is that convergent validity has not been demonstrated between the EDS and an existing, validated, quality-of-life instrument. The absence of data on such an instrument in our population prevented us from assessing the convergent validity of the EDS. However, the EDS was derived from the Health Distress scale of the validated Medical Outcomes Study Health Perceptions Index, which was designed for use in a wide range of medical conditions, including life-threatening conditions such as cancer. 11 Although ED is not in itself life-threatening, it clearly exacts an emotional toll on men and may be an early symptom of cardiovascular disease. 28, 29 The current analysis of pooled data from five randomized, double-blind, placebo-controlled trials of sildenafil revealed that even men with mild ED reported significant bother on the EDS, and that the bother improved with successful treatment of ED. The greatest changes on the EDS were observed for frustration and discouragement rather than for feelings of worry, despair or being weighed down by a health condition. Nevertheless, significant improvements were observed in all of these measures of bother. Although further study is needed to establish convergent validity of the EDS, our results suggest that the EDS may be useful for assessing the level at which ED is a bother before and after treatment for ED.
